We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing
Read MoreHide Full Article
Moderna, Inc. (MRNA - Free Report) announced that the FDA’s Vaccines and Related Biological Products Advisory Committee has voted in favor of FDA granting an emergency use authorization (EUA) to its mRNA-based coronavirus vaccine candidate, mRNA-1273. From the panel, 20 members voted in support of providing the EUA, while there was no vote against it. The same committee had voted 17-4 recommending Pfizer (PFE - Free Report) /BioNTech’s (BNTX - Free Report) mRNA-based vaccine, BNT162b2. One member abstained during both advisory committee meetings.
We note that a recommendation for EUA was expected from the advisory committee as a briefing document released by the FDA before the meeting mentioned that mRNA-1273 was safe and effective in preventing COVID-19. The FDA is likely to follow advisory committee’s recommendation and Moderna may get an EUA in a day or two.
The recommendation was based on the totality of scientific evidence shared by Moderna, including data from the pivotal phase III COVE study evaluating mRNA-1273 in adult patients. The candidate demonstrated an encouraging efficacy rate of 94.1% during primary efficacy analysis as well as full protection against severe COVID-19 cases. The press release stated that the majority of local solicited adverse events occurred within the first one to two days after injection and remained for a median of one to two days.
A National Institutes of Health-appointed independent Data Safety Monitoring Board will monitor all participants in the phase III study for two years after the second dose, to assess long-term protection and safety.
Moderna’s shares have skyrocketed 620.8% so far this year compared with the industry’s rise of 8.4%.
The company has started evaluating mRNA-1273 in adolescent patients aged 12 years or more. It plans to generate sufficient data by mid-2021 to support regulatory filings, seeking emergency authorization/approval for use of mRNA-1273 in adolescents. The company also has plans to initiate one surveillance study for evaluating the candidate in pregnant women and two other surveillance studies — active follow-up for safety and real-world effectiveness study.
The company is ready to ship 20 million doses to the U.S. government by the end of this year following the potential EUA. The company has signed an agreement to deliver another 180 million doses of mRNA-1273 to the U.S. government during the first half of 2021. The U.S. government has the option to purchase additional 300 million doses of mRNA-1273. The company has built enough manufacturing capacity to deliver 1 billion doses across the globe in 2021. The company is also focusing on the efficient distribution of the vaccine. The vaccine can remain stable at standard refrigerator temperatures of 2° to 8°C for 30 days. It now added that local transport can be included, which can distribute the vaccine under controlled conditions in a liquid state at 2-8°C.
Pfizer/BioNTech, have received emergency use approval for their vaccine in at least six countries including the United States and the United Kingdom. However, conditional marketing authorization requests for both candidates are under review in Europe. Extraordinary meetings for assessing marketing authorization application for BNT162b2 and mRNA-1273 have been scheduled on Dec 21, 2020 and Jan 6, 2021, respectively. Moderna has several other regulatory applications under review across different countries and also multiple supply agreements in place.
Meanwhile, AstraZeneca (AZN - Free Report) /Oxford University’s potential vaccine candidate, AZD1222 was, on average, about 70% effective in preventing COVID-19, per interim data released from late-stage studies. J&J and CureVac’s COVID-19 vaccine candidates are also in late-stage development and study data are expected next year.
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Image: Bigstock
Moderna's (MRNA) COVID-19 Vaccine Gets FDA Panel's Backing
Moderna, Inc. (MRNA - Free Report) announced that the FDA’s Vaccines and Related Biological Products Advisory Committee has voted in favor of FDA granting an emergency use authorization (EUA) to its mRNA-based coronavirus vaccine candidate, mRNA-1273. From the panel, 20 members voted in support of providing the EUA, while there was no vote against it. The same committee had voted 17-4 recommending Pfizer (PFE - Free Report) /BioNTech’s (BNTX - Free Report) mRNA-based vaccine, BNT162b2. One member abstained during both advisory committee meetings.
We note that a recommendation for EUA was expected from the advisory committee as a briefing document released by the FDA before the meeting mentioned that mRNA-1273 was safe and effective in preventing COVID-19. The FDA is likely to follow advisory committee’s recommendation and Moderna may get an EUA in a day or two.
The recommendation was based on the totality of scientific evidence shared by Moderna, including data from the pivotal phase III COVE study evaluating mRNA-1273 in adult patients. The candidate demonstrated an encouraging efficacy rate of 94.1% during primary efficacy analysis as well as full protection against severe COVID-19 cases. The press release stated that the majority of local solicited adverse events occurred within the first one to two days after injection and remained for a median of one to two days.
A National Institutes of Health-appointed independent Data Safety Monitoring Board will monitor all participants in the phase III study for two years after the second dose, to assess long-term protection and safety.
Moderna’s shares have skyrocketed 620.8% so far this year compared with the industry’s rise of 8.4%.
The company has started evaluating mRNA-1273 in adolescent patients aged 12 years or more. It plans to generate sufficient data by mid-2021 to support regulatory filings, seeking emergency authorization/approval for use of mRNA-1273 in adolescents. The company also has plans to initiate one surveillance study for evaluating the candidate in pregnant women and two other surveillance studies — active follow-up for safety and real-world effectiveness study.
The company is ready to ship 20 million doses to the U.S. government by the end of this year following the potential EUA. The company has signed an agreement to deliver another 180 million doses of mRNA-1273 to the U.S. government during the first half of 2021. The U.S. government has the option to purchase additional 300 million doses of mRNA-1273. The company has built enough manufacturing capacity to deliver 1 billion doses across the globe in 2021. The company is also focusing on the efficient distribution of the vaccine. The vaccine can remain stable at standard refrigerator temperatures of 2° to 8°C for 30 days. It now added that local transport can be included, which can distribute the vaccine under controlled conditions in a liquid state at 2-8°C.
Pfizer/BioNTech, have received emergency use approval for their vaccine in at least six countries including the United States and the United Kingdom. However, conditional marketing authorization requests for both candidates are under review in Europe. Extraordinary meetings for assessing marketing authorization application for BNT162b2 and mRNA-1273 have been scheduled on Dec 21, 2020 and Jan 6, 2021, respectively. Moderna has several other regulatory applications under review across different countries and also multiple supply agreements in place.
Meanwhile, AstraZeneca (AZN - Free Report) /Oxford University’s potential vaccine candidate, AZD1222 was, on average, about 70% effective in preventing COVID-19, per interim data released from late-stage studies. J&J and CureVac’s COVID-19 vaccine candidates are also in late-stage development and study data are expected next year.
Moderna, Inc. Price
Moderna, Inc. price | Moderna, Inc. Quote
Zacks Rank
Moderna currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>